Hearing Loss in Children with Congenital Cytomegalovirus Infection: Natural History and Antiviral Treatment
Congenital cytomegalovirus (CMV) infection occurs in an estimated 4.5 per 1,000 live birth children in the United States, which corresponds to 16,000 infected newborns annually. Approximately 10-15% of infected infants present with a spectrum of mildly to severely symptomatic disease at birth and are at high risk of neurodevelopmental sequelae. Among the 85-90% infants who are asymptomatic at birth, 10-15% will have sensorineural hearing loss (SNHL), at birth or later. Thus, most cases of congenital CMV-related SNHL are expected in infants with asymptomatic congenital CMV infection, who are not typically identified because universal newborn CMV screening is not recommended, and about half of those infants may pass the newborn hearing screening. The American Academy of Pediatrics recommends treatment with valganciclovir for infants with moderate to severe symptomatic congenital CMV disease who can start treatment within 1 month of life. Evidence from randomized controlled trials for antiviral treatment of asymptomatic infants or those in whom SNHL is the only sign is lacking, and so is consensus among experts. This presentation will cover the natural history, risk factors and prevalence of SNHL among children with congenital CMV infection and available evidence and knowledge gaps on short and long-term effects of antiviral treatment for children with congenital CMV-related sensorineural hearing loss.
- Describe the natural history of sensorineural hearing loss (SNHL) among children with congenital cytomegalovirus (CMV) infection.
- Describe the prevalence of SNHL among children with congenital CMV infection identified as symptomatic or asymptomatic at birth.
- Discuss available evidence and knowledge gaps on short and long-term effects of antiviral treatment for children with congenital CMV-related sensorineural hearing loss.
This presentation has not yet been uploaded.
No handouts have been uploaded.
Tatiana Lanzieri | Primary Presenter
Tatiana M. Lanzieri, M.D., M.P.H., is a medical epidemiologist with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention. She has over 20 years of experience in infectious disease epidemiology, surveillance, and outbreak investigation.
Financial - No relevant financial relationship exists.
Nonfinancial - No relevant nonfinancial relationship exists.